Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Layton, UT
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Layton, UT
Click here to add this to my saved trials
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Jordan, UT
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bristol, TN
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Vaccine Research & Education Unit
mi
from
Iowa City, IA
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Vaccine Research & Education Unit
mi
from
Iowa City, IA
Click here to add this to my saved trials
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center - Infectious Diseases
mi
from
Cincinnati, OH
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center - Infectious Diseases
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine - Molecular Virology and Microbiology
mi
from
Houston, TX
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine - Molecular Virology and Microbiology
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
A Phase I Study In Healthy Adults To Assess The Safety And Immunogenicity Of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
A Phase I Study In Healthy Adults To Assess The Safety And Immunogenicity Of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Stockbridge, GA
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Status: Enrolling
Updated:  12/31/1969
Optimal Health Research
mi
from
Rockville, MD
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Status: Enrolling
Updated: 12/31/1969
Optimal Health Research
mi
from
Rockville, MD
Click here to add this to my saved trials
Open-Label Influenza Vaccine Evaluation
Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Open-Label Influenza Vaccine Evaluation
Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Impact of Rapid Flu Testing in BMC ED
Proposal to Evaluate the Impact of Point of Care Liat Influenza A/B Testing in the Emergency Department at Boston Medical Center
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Impact of Rapid Flu Testing in BMC ED
Proposal to Evaluate the Impact of Point of Care Liat Influenza A/B Testing in the Emergency Department at Boston Medical Center
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Status: Enrolling
Updated:  12/31/1969
The Hope Clinic of the Emory Vaccine Center
mi
from
Atlanta, GA
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Status: Enrolling
Updated: 12/31/1969
The Hope Clinic of the Emory Vaccine Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 037
mi
from
Anaheim, CA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 037
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 029
mi
from
Redding, CA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 029
mi
from
Redding, CA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 003
mi
from
San Diego, CA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 003
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 016
mi
from
Colorado Springs, CO
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 016
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 035
mi
from
Milford, CT
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 035
mi
from
Milford, CT
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 031
mi
from
Hollywood, FL
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 031
mi
from
Hollywood, FL
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 009
mi
from
Jacksonville, FL
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 009
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 030
mi
from
Stockbridge, GA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 030
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 010
mi
from
Boise, ID
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 010
mi
from
Boise, ID
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 034
mi
from
Meridian, ID
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 034
mi
from
Meridian, ID
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 021
mi
from
Council Bluffs, IA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 021
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 023
mi
from
Wichita, KA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 023
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 012
mi
from
Bardstown, KY
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 012
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 018
mi
from
Metairie, LA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 018
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 026
mi
from
Biloxi, MS
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 026
mi
from
Biloxi, MS
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 014
mi
from
Saint Louis, MO
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 014
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 011
mi
from
Omaha, NE
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 011
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 024
mi
from
Las Vegas, NV
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 024
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 008
mi
from
Rochester, NY
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 008
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 005
mi
from
Wilmington, NC
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 005
mi
from
Wilmington, NC
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 036
mi
from
Winston-Salem, NC
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 036
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 004
mi
from
Cleveland, OH
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 004
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 015
mi
from
Oklahoma City, OK
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 015
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 013
mi
from
Warwick, RI
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 013
mi
from
Warwick, RI
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 033
mi
from
Mount Pleasant, SC
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 033
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 001
mi
from
Nashville, TN
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 001
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 002
mi
from
Dallas, TX
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 002
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 025
mi
from
Tomball, TX
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 025
mi
from
Tomball, TX
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 027
mi
from
Salt Lake City, UT
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 027
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 020
mi
from
South Jordan, UT
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 020
mi
from
South Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 022
mi
from
West Jordan, UT
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 022
mi
from
West Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated:  12/31/1969
Sanofi Pasteur Investigational Site 038
mi
from
Norfolk, VA
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Status: Enrolling
Updated: 12/31/1969
Sanofi Pasteur Investigational Site 038
mi
from
Norfolk, VA
Click here to add this to my saved trials
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
Randomized Trial of Peer-to-Peer Versus Pharmacist Education to Improve Older Adults' Vaccination Knowledge Through the Senior Center Model of Care
Status: Enrolling
Updated:  12/31/1969
Rutgers University
mi
from
Piscataway, NJ
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
Randomized Trial of Peer-to-Peer Versus Pharmacist Education to Improve Older Adults' Vaccination Knowledge Through the Senior Center Model of Care
Status: Enrolling
Updated: 12/31/1969
Rutgers University
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Savannah, GA
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials